Nektar Therapeutics (NKTR) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Nektar Therapeutics Revenue Highlights

Latest Revenue (Y)

$90.12M

Latest Revenue (Q)

$24.12M

Main Segment (Y)

Non Cash Royalty Revenue Related To Sale Of Future Royalties

Main Geography (Y)

Non-US

Nektar Therapeutics Revenue by Period

Nektar Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$90.12M	-2.10%
2022-12-31	$92.06M	-9.67%
2021-12-31	$101.91M	-33.36%
2020-12-31	$152.91M	33.41%
2019-12-31	$114.62M	-90.40%
2018-12-31	$1.19B	287.81%
2017-12-31	$307.71M	86.00%
2016-12-31	$165.44M	-28.32%
2015-12-31	$230.78M	14.99%
2014-12-31	$200.71M	34.77%
2013-12-31	$148.92M	83.42%
2012-12-31	$81.19M	13.59%
2011-12-31	$71.48M	-55.06%
2010-12-31	$159.04M	121.10%
2009-12-31	$71.93M	-20.24%
2008-12-31	$90.19M	-66.97%
2007-12-31	$273.03M	25.40%
2006-12-31	$217.72M	72.41%
2005-12-31	$126.28M	10.51%
2004-12-31	$114.27M	7.54%
2003-12-31	$106.26M	12.03%
2002-12-31	$94.84M	22.43%
2001-12-31	$77.47M	50.05%
2000-12-31	$51.63M	24.83%
1999-12-31	$41.36M	89.76%
1998-12-31	$21.80M	34.13%
1997-12-31	$16.25M	135.49%
1996-12-31	$6.90M	102.94%
1995-12-31	$3.40M	100.00%
1994-12-31	$1.70M	-

Nektar Therapeutics generated $90.12M in revenue during NA 2023, up -2.10% compared to the previous quarter, and up 7.55% compared to the same period a year ago.

Nektar Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-09-30	$24.12M	2.70%
2024-06-30	$23.49M	8.55%
2024-03-31	$21.64M	-9.40%
2023-12-31	$23.89M	-1.07%
2023-09-30	$24.14M	17.78%
2023-06-30	$20.50M	-5.07%
2023-03-31	$21.59M	-1.95%
2022-12-31	$22.02M	-6.78%
2022-09-30	$23.63M	9.45%
2022-06-30	$21.59M	-13.04%
2022-03-31	$24.82M	-0.75%
2021-12-31	$25.01M	0.35%
2021-09-30	$24.92M	-12.03%
2021-06-30	$28.33M	19.80%
2021-03-31	$23.65M	0.79%
2020-12-31	$23.46M	-21.88%
2020-09-30	$30.03M	-38.52%
2020-06-30	$48.85M	-3.41%
2020-03-31	$50.57M	49.35%
2019-12-31	$33.86M	15.89%
2019-09-30	$29.22M	25.32%
2019-06-30	$23.32M	-17.39%
2019-03-31	$28.22M	-29.14%
2018-12-31	$39.83M	43.46%
2018-09-30	$27.76M	-97.45%
2018-06-30	$1.09B	2761.06%
2018-03-31	$38.02M	-60.18%
2017-12-31	$95.47M	-37.57%
2017-09-30	$152.93M	342.13%
2017-06-30	$34.59M	39.88%
2017-03-31	$24.73M	-33.97%
2016-12-31	$37.45M	3.07%
2016-09-30	$36.34M	10.89%
2016-06-30	$32.77M	-44.35%
2016-03-31	$58.88M	49.56%
2015-12-31	$39.37M	-34.33%
2015-09-30	$59.95M	164.56%
2015-06-30	$22.66M	-79.17%
2015-03-31	$108.80M	456.47%
2014-12-31	$19.55M	-85.28%
2014-09-30	$132.87M	366.00%
2014-06-30	$28.51M	44.22%
2014-03-31	$19.77M	-36.52%
2013-12-31	$31.15M	-48.86%
2013-09-30	$60.91M	79.87%
2013-06-30	$33.86M	47.20%
2013-03-31	$23.00M	8.79%
2012-12-31	$21.15M	14.85%
2012-09-30	$18.41M	-22.26%
2012-06-30	$23.68M	31.95%
2012-03-31	$17.95M	13.73%
2011-12-31	$15.78M	-41.69%
2011-09-30	$27.07M	56.18%
2011-06-30	$17.33M	53.39%
2011-03-31	$11.30M	-75.07%
2010-12-31	$45.31M	19.48%
2010-09-30	$37.92M	-10.90%
2010-06-30	$42.56M	28.06%
2010-03-31	$33.24M	-14.80%
2009-12-31	$39.01M	281.58%
2009-09-30	$10.22M	-21.29%
2009-06-30	$12.99M	33.75%
2009-03-31	$9.71M	-65.75%
2008-12-31	$28.35M	32.25%
2008-09-30	$21.44M	5.09%
2008-06-30	$20.40M	2.05%
2008-03-31	$19.99M	-69.60%
2007-12-31	$65.77M	-

Nektar Therapeutics generated $24.12M in revenue during Q3 2024, up 2.70% compared to the previous quarter, and up 117.68% compared to the same period a year ago.

Nektar Therapeutics Revenue Breakdown

Nektar Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product	$20.68M	$20.35M	$23.73M	$17.50M	$20.12M
License Collaboration And Other Revenue	$520.00K	$1.91M	$436.00K	$55.85M	$16.98M
Non Cash Royalty Revenue Related To Sale Of Future Royalties	$68.92M	$69.79M	$77.75M	$48.56M	$36.30M
Royalty	-	-	-	$31.00M	$41.22M

Nektar Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Non Cash Royalty Revenue Related To Sale Of Future Royalties (76.48%), Product (22.95%), and License Collaboration And Other Revenue (0.58%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Product	$8.02M	$6.03M	$5.48M	$5.82M	$4.66M	$4.72M	$4.38M	$4.97M	$5.31M	$5.69M	$5.89M	$5.19M	$7.85M	$4.79M	$2.88M	$5.69M	$5.49M	$3.44M	$5.82M	$5.56M
Non Cash Royalty Revenue Related To Sale Of Future Royalties	$15.73M	$15.51M	$18.06M	$18.17M	$15.83M	$16.86M	$17.63M	$18.34M	$16.26M	$17.56M	$19.08M	$19.41M	$20.46M	$18.80M	$20.56M	$10.42M	$7.68M	$9.89M	$8.72M	$10.26M
License Collaboration And Other Revenue	$378.00K	$97.00K	$341.00K	$155.00K	$9.00K	$15.00K	$17.00K	$314.00K	$9.00K	$1.57M	$40.00K	$314.00K	$28.00K	$54.00K	$428.00K	$1.63M	$26.27M	$27.52M	$7.12M	$3.12M
Royalty	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-412.00K	$12.29M	$9.40M	$9.72M	$12.21M	$10.28M

Nektar Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Non Cash Royalty Revenue Related To Sale Of Future Royalties (65.21%), Product (33.22%), and License Collaboration And Other Revenue (1.57%).

Nektar Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Non-US	$78.64M	$82.21M	$91.79M	$87.95M	$87.52M
UNITED STATES	$11.48M	$9.84M	$10.11M	$64.97M	$27.09M

Nektar Therapeutics's latest annual revenue breakdown by geography, as of Dec 23: Non-US (87.26%), and UNITED STATES (12.74%).

Nektar Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
CTMX	CytomX Therapeutics	$101.21M	$33.43M
SPRO	Spero Therapeutics	$96.73M	$13.47M
NKTR	Nektar Therapeutics	$90.12M	$24.12M
ASMB	Assembly Biosciences	$7.16M	$6.84M
NXTC	NextCure	-	-
TIL	Instil Bio	-	-
NLTX	Neurogene	-	-
ACHL	Achilles Therapeutics	-	-
NUVB	Nuvation Bio	-	$727.00K

NKTR Revenue FAQ

What is Nektar Therapeutics’s yearly revenue?

Nektar Therapeutics's yearly revenue for 2023 was $90.12M, representing a decrease of -2.10% compared to 2022. The company's yearly revenue for 2022 was $92.06M, representing a decrease of -9.67% compared to 2021. NKTR's yearly revenue for 2021 was $101.91M, representing a decrease of -33.36% compared to 2020.

What is Nektar Therapeutics’s quarterly revenue?

Nektar Therapeutics's quarterly revenue for Q3 2024 was $24.12M, a 2.70% increase from the previous quarter (Q2 2024), and a -0.08% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $23.49M, a 8.55% increase from the previous quarter (Q1 2024), and a 14.59% increase year-over-year (Q2 2023). NKTR's quarterly revenue for Q1 2024 was $21.64M, a -9.40% decrease from the previous quarter (Q4 2023), and a 0.21% increase year-over-year (Q1 2023).

What is Nektar Therapeutics’s revenue growth rate?

Nektar Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -11.56%, and for the last 5 years (2019-2023) was -21.37%.

What are Nektar Therapeutics’s revenue streams?

Nektar Therapeutics's revenue streams in c 23 are Product, License Collaboration And Other Revenue, and Non Cash Royalty Revenue Related To Sale Of Future Royalties. Product generated $20.68M in revenue, accounting 22.95% of the company's total revenue, up 1.64% year-over-year. License Collaboration And Other Revenue generated $520K in revenue, accounting 0.58% of the company's total revenue, down -72.82% year-over-year. Non Cash Royalty Revenue Related To Sale Of Future Royalties generated $68.92M in revenue, accounting 76.48% of the company's total revenue, down -1.25% year-over-year.

What is Nektar Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Nektar Therapeutics was Non Cash Royalty Revenue Related To Sale Of Future Royalties. This segment made a revenue of $68.92M, representing 76.48% of the company's total revenue.